During the first nine months of 2014, revenue from collaborative and licensing agreements was mainly composed of: (i) manufacturing and research and development services (0.9 million euros); and (ii) revenue from licensed technologies and products (0.6 million euros).
As of September 30, 2014, government financing for research expenditures included: (i) an estimate of the income accrued during the period for subsidies received and to be received (0.5 million euros) and (ii) 75% of the research tax credit for 2014, estimated as of June 30, 2014 (7.2 million euros).
Si le fichier PDF ne s'affiche pas ou pour le télécharger, cliquez ici.
Pour consulter le fichier PDF en intégralité, cliquez ici.
|TRANSGENE||Euronext Paris||2.58 (c)||1.98%||72 486|